Open AccessN2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma
Author(s) -
Wolfgang Wick,
Susan Dettmer,
Anne Berberich,
Tobias Keßler,
Irini KarapanagiotouSchenkel,
Antje Wick,
Frank Winkler,
Elke Pfaff,
Benedikt Brors,
Jürgen Debus,
Andreas Unterberg,
Martin Bendszus,
Christel HeroldMende,
Andreas Eisenmenger,
Andreas von Deimling,
David Jones,
Stefan M. Pfister,
Felix Sahm,
Michael Platten
Publication year - 2018
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/noy161
Subject(s) - glioblastoma , medicine , radiation therapy , oncology , temozolomide , cancer research
Patients with glioblastoma without O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation are unlikely to benefit from alkylating chemotherapy with temozolomide (TMZ). Trials aiming at replacing TMZ with targeted agents in unselected patient populations have failed to demonstrate any improvement of survival. Advances in molecular understanding and diagnostic precision enable identification of key genetic alterations in a timely manner and in principle allow treatments with targeted compounds based on molecular markers.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom